|
|
A New Biochemical Target to Attack Resistant Tuberculosis Bacteriae
Mar 16, 2005, 12:55, Reviewed by: Dr.
|
|
"We've been able to find at least the beginnings of a class of compounds that we can start working with and that we know is biochemically active against the TB bacteria in culture and in small animals."
|
By University of Pennsylvania School of Medicine ,
A worldwide health problem, tuberculosis kills more people than any other bacterial infection. The World Health Organization estimates that two billion people are infected with TB, and that two million people die each year from the disease.
However, due to multi-drug resistance and a protracted medication regimen, it is extremely difficult to treat. Hence, there is still a great deal of interest in developing new anti-tubercular drugs.
Researchers at the University of Pennsylvania School of Medicine have identified a biochemical target that could lead to a new class of antibiotics to fight TB. They report their findings in this week's online edition of the Proceedings of the National Academy of Sciences.
In a proof-of-principle study, Harvey Rubin, MD, PhD, Professor of Medicine, Division of Infectious Diseases, and colleagues were able to stop the bacteria from multiplying by inhibiting the first step in a common biochemical pathway.
This pathway is responsible for making the energy molecules all cells need to survive.
First author Edward Weinstein, an MD/PhD student, Rubin, and colleagues characterized the pathway and showed that an important enzyme in it is a key target for anti-TB agents.
The pathway, explains Rubin, is like a series of links in a chain, with enzymes facilitating reactions along the way. "We discovered that if you inhibit the very first enzyme in the chain, you inhibit everything else downstream and eventually the bacteria die," he explains.
The research group tested phenothiazine, a drug used in the past to treat schizophrenia, in cultures of Mycobacterium tuberculosis, the bacterium that causes TB. They found that phenothiazines killed the bacterium in culture and suppressed its growth in mice with acute TB infection.
While the effect on the growth of TB in mice was small, it suggested that a valid target was identified. The research group went on to show that the enzyme disabled by the phenothiazines is called type II NADH dehydrogenase and is a unique and important antimicrobial target.
"What we have now is a new target in TB," says Rubin. "We've been able to find at least the beginnings of a class of compounds that we can start working with and that we know is biochemically active against the TB bacteria in culture and in small animals."
Is it a new drug for tuberculosis? Not yet, cautions Rubin. It's premature to say that this class of drugs will cure TB, but it does represent the start of basic research towards that, he concludes.
Next steps include more investigations on inhibitors of the NADH biochemical pathway in TB, and the development of high-throughput screens to find better and safer inhibitors of type II NADH dehydrogenase. 
- This week's online edition of the Proceedings of the National Academy of Sciences
University of Pennsylvania School of Medicine
This work was supported by grants from the National Institutes of Health. Rubin and Weinstein's coauthors are Takahiro Yano, Lin-Sheng Li, David Avarbock, Andrew Avarbock and Douglas Helm from Penn, and Andrew McColm, Ken Duncan, and John T. Lonsdale from GlaxoSmithKline ( Collegeville, PA and Stevenage, UK ). Animal studies were conducted at GlaxoSmithKline. Penn researchers report no conflicts of interest.
PENN Medicine is a $2.7 billion enterprise dedicated to the related missions of medical education, biomedical research, and high-quality patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine ( founded in 1765 as the nation's first medical school ) and the University of Pennsylvania Health System ( created in 1993 as the nation's first integrated academic health system ).
Penn's School of Medicine is ranked #3 in the nation for receipt of NIH research funds; and ranked #4 in the nation in U.S. News & World Report's most recent ranking of top research-oriented medical schools. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.
The University of Pennsylvania Health System includes three owned hospitals [Hospital of the University of Pennsylvania, which is consistently ranked one of the nation's few "Honor Roll" hospitals by U.S. News & World Report; Pennsylvania Hospital, the nation's first hospital; and Presbyterian Medical Center]; a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home care and hospice.
Contact: Karen Kreeger
[email protected]
215-349-5658
University of Pennsylvania Medical Center
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
Top of Page
|
|
|
|
